213 related articles for article (PubMed ID: 23790737)
1. Hyaluronic acid in the pleural fluid of patients with malignant pleural mesothelioma.
Fujimoto N; Gemba K; Asano M; Fuchimoto Y; Wada S; Ono K; Ozaki S; Kishimoto T
Respir Investig; 2013 Jun; 51(2):92-7. PubMed ID: 23790737
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma: An updated meta-analysis.
Gao R; Wang F; Wang Z; Wu Y; Xu L; Qin Y; Shi H; Tong Z
Medicine (Baltimore); 2019 Apr; 98(14):e14979. PubMed ID: 30946324
[TBL] [Abstract][Full Text] [Related]
3. Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma.
Creaney J; Dick IM; Segal A; Musk AW; Robinson BW
Lung Cancer; 2013 Dec; 82(3):491-8. PubMed ID: 24161718
[TBL] [Abstract][Full Text] [Related]
4. Utility of hyaluronic acid in pleural fluid for differential diagnosis of pleural effusions: likelihood ratios for malignant mesothelioma.
Atagi S; Ogawara M; Kawahara M; Sakatani M; Furuse K; Ueda E; Yamamoto S
Jpn J Clin Oncol; 1997 Oct; 27(5):293-7. PubMed ID: 9390204
[TBL] [Abstract][Full Text] [Related]
5. Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center.
Otoshi T; Kataoka Y; Ikegaki S; Saito E; Matsumoto H; Kaku S; Shimada M; Hirabayashi M
PLoS One; 2017; 12(10):e0185850. PubMed ID: 28968445
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic method for malignant pleural effusion distinguishing malignant mesothelioma from lung cancer using pleural carcinoembryonic antigen and hyaluronic acid levels.
Saraya T; Ohkuma K; Fujiwara M; Ishii H
Medicine (Baltimore); 2022 Jan; 101(1):e28517. PubMed ID: 35029914
[TBL] [Abstract][Full Text] [Related]
7. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
Muley T; Dienemann H; Herth FJ; Thomas M; Meister M; Schneider J
J Thorac Oncol; 2013 Jul; 8(7):947-51. PubMed ID: 23777840
[TBL] [Abstract][Full Text] [Related]
8. The established and future biomarkers of malignant pleural mesothelioma.
Panou V; Vyberg M; Weinreich UM; Meristoudis C; Falkmer UG; Røe OD
Cancer Treat Rev; 2015 Jun; 41(6):486-95. PubMed ID: 25979846
[TBL] [Abstract][Full Text] [Related]
9. Aberrant DNA methylation profile in pleural fluid for differential diagnosis of malignant pleural mesothelioma.
Fujii M; Fujimoto N; Hiraki A; Gemba K; Aoe K; Umemura S; Katayama H; Takigawa N; Kiura K; Tanimoto M; Kishimoto T
Cancer Sci; 2012 Mar; 103(3):510-4. PubMed ID: 22146010
[TBL] [Abstract][Full Text] [Related]
10. Concentration of hyaluronic acid in pleural fluid as a diagnostic aid for malignant mesothelioma.
Pettersson T; Fröseth B; Riska H; Klockars M
Chest; 1988 Nov; 94(5):1037-9. PubMed ID: 3180855
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.
Battolla E; Canessa PA; Ferro P; Franceschini MC; Fontana V; Dessanti P; Pinelli V; Morabito A; Fedeli F; Pistillo MP; Roncella S
Anticancer Res; 2017 Mar; 37(3):1387-1391. PubMed ID: 28314308
[TBL] [Abstract][Full Text] [Related]
12. CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives.
Cortes-Dericks L; Schmid RA
Respir Res; 2017 Apr; 18(1):58. PubMed ID: 28403901
[TBL] [Abstract][Full Text] [Related]
13. Cytological diagnosis of malignant mesothelioma--improvement by additional analysis of hyaluronic acid in pleural effusions.
Welker L; Müller M; Holz O; Vollmer E; Magnussen H; Jörres RA
Virchows Arch; 2007 Apr; 450(4):455-61. PubMed ID: 17377812
[TBL] [Abstract][Full Text] [Related]
14. The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma.
Muraoka T; Soh J; Toyooka S; Aoe K; Fujimoto N; Hashida S; Maki Y; Tanaka N; Shien K; Furukawa M; Yamamoto H; Asano H; Tsukuda K; Kishimoto T; Otsuki T; Miyoshi S
Lung Cancer; 2013 Dec; 82(3):485-90. PubMed ID: 24168922
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma.
Yamada S; Tabata C; Tabata R; Fukuoka K; Nakano T
Clin Chem Lab Med; 2011 Oct; 49(10):1721-6. PubMed ID: 21692685
[TBL] [Abstract][Full Text] [Related]
16. [A case of malignant pleural mesothelioma with elevation of G-CSF and CYFRA in the serum and pleural fluid].
Inoue C; Kato S; Higuchi K; Inoue H
Nihon Kokyuki Gakkai Zasshi; 2007 Mar; 45(3):243-7. PubMed ID: 17419436
[TBL] [Abstract][Full Text] [Related]
17. Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma.
Grigoriu B; Chahine B; Zerimech F; Grégoire M; Balduyck M; Copin MC; Devos P; Lassalle P; Scherpereel A
Clin Biochem; 2009 Jul; 42(10-11):1046-50. PubMed ID: 19302997
[TBL] [Abstract][Full Text] [Related]
18. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
Pass HI; Levin SM; Harbut MR; Melamed J; Chiriboga L; Donington J; Huflejt M; Carbone M; Chia D; Goodglick L; Goodman GE; Thornquist MD; Liu G; de Perrot M; Tsao MS; Goparaju C
N Engl J Med; 2012 Oct; 367(15):1417-27. PubMed ID: 23050525
[TBL] [Abstract][Full Text] [Related]
19. Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies.
Fuhrman C; Duche JC; Chouaid C; Abd Alsamad I; Atassi K; Monnet I; Tillement JP; Housset B
Clin Biochem; 2000 Jul; 33(5):405-10. PubMed ID: 11018693
[TBL] [Abstract][Full Text] [Related]
20. c-Met expression and MET amplification in malignant pleural mesothelioma.
Bois MC; Mansfield AS; Sukov WR; Jenkins SM; Moser JC; Sattler CA; Smith CY; Molina JR; Peikert T; Roden AC
Ann Diagn Pathol; 2016 Aug; 23():1-7. PubMed ID: 27402216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]